Coronavirus

As COVID-19 hospitalizations increase at the opening of the respiratory virus season, the first "seasonal" vaccine against the virus is ready for roll-out, says the FDA.

"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."

Vaccination against SARS-CoV-2 may decrease the symptoms of post-COVID conditions, such as abdominal pain and weakness, according to new study.

Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.

A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.

Patients hospitalized with COVID-19 were 2-times more likely to develop persistent hypertension than their influenza counterparts, according to results.

A daily dose of clinical news on Patient Care you may have missed.

The arrival of COVID-19 vaccines challenged many people for the first time to understand the actual public health role of vaccination. With the RSV shots, it may be round 2.

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

The real-world analysis measured the benefit of primary vaccination and of a booster and found the latter dependent upon local disease incidence and risk for severe disease.

In the post COVID-19 pandemic health care emergency era, private and public insurance entities will continue full coverage of the shots - but what about the uninsured?

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.

The FDA advisory committee will review all current surveillance data and recommend which strain/s to include in updated COVID-19 vaccines for the 2023-2024 vaccination campaign.

Your daily dose of clinical news you may have missed.

More research is needed to determine whether metformin is also effective in patients with lower body mass index or with previous infection, said researchers.

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.

A Feinberg School of Medicine physiatrist with long experience assessing long COVID talks specifically about common neurologic sequelae of the infection.

Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.

The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.

Neutralizing antibodies were lowest among Janssen volunteers at 1 month post-vaccination but at 6 months afterward, the picture was much different.

Your daily dose of clinical news you may have missed.

The US health care provider community continues to do its collective best to cope with the protean condition that is long COVID, according to recent poll findings.

Persons with long COVID showed compensatory neural activity in certain brain areas while performing memory tasks as long as 6 months after infection resolved.

When combined, fluvoxamine and inhaled budesonide appear more likely than either agent alone to reduce risk of early COVID-19 becoming severe, say TOGETHER investigators.

The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.